Patient willingness to de-escalate adjuvant therapy based on predictive biomarker results in stage IIB-IIID melanoma: A cross-sectional survey
Open Access
- 25 September 2026
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 248, 117061
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Krebshilfe
This publication has 29 references indexed in Scilit:
- Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based studyEuropean Journal of Cancer, 2025
- Patient perceptions around the use of clinico-pathologic and genomic tools in the management of early breast cancerBreast Cancer Research and Treatment, 2025
- Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialEuropean Journal of Cancer, 2024
- Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanomaCancer Treatment Reviews, 2024
- Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsyEuropean Journal of Cancer, 2024
- Understanding communication between patients and healthcare professionals regarding comprehensive biomarker testing in precision oncology: A scoping reviewCancer Medicine, 2024
- Advanced cancer patient preferences for receiving molecular profiling resultsPsycho-Oncology, 2020
- Effect of a Patient and Clinician Communication-Priming Intervention on Patient-Reported Goals-of-Care Discussions Between Patients With Serious Illness and CliniciansJAMA Internal Medicine, 2018
- Does biomarker information impact breast cancer patients’ preferences and physician recommendation for adjuvant chemotherapy?Breast Cancer Research and Treatment, 2017
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of internal medicine (1960), 2006